A New Pill for High Cholesterol: Understanding the Impact of Enlicitide
For millions of people living with cardiovascular disease or those at high risk for a heart attack or stroke, managing “bad” cholesterol (LDL-C) is a lifelong battle. While statins are the gold standard, many patients still can’t reach their target LDL levels, leaving them with a dangerous amount of residual risk. Until now, the most powerful tools to bridge this gap—PCSK9 inhibitors—required subcutaneous injections.
That is changing. New clinical data reveals that enlicitide, a once-daily pill, can lower LDL cholesterol with efficacy similar to those injections, potentially transforming how physicians and patients manage high-risk lipid profiles.
What is Enlicitide and How Does It Work?
To understand why enlicitide is a breakthrough, it’s important to understand the role of the PCSK9 protein. In a healthy system, the liver uses LDL receptors to clear bad cholesterol from the bloodstream. However, the PCSK9 protein binds to these receptors and triggers their degradation, effectively reducing the liver’s ability to remove cholesterol.
Enlicitide is an oral PCSK9 inhibitor. It works through the same biological mechanism as injectable monoclonal antibodies, such as evolocumab and alirocumab. By blocking the PCSK9 protein from binding to the LDL receptor, enlicitide increases the number of available receptors on the liver’s surface, which enhances the clearance of LDL-C from the blood.
The foundational work for this class of medication originated from the Dallas Heart Study at UT Southwestern, led by Helen Hobbs, M.D., and Jonathan Cohen, Ph.D.
The CORALreef Lipids Trial: Key Findings
The efficacy of this oral medication was put to the test in the phase 3 CORALreef Lipids Trial. The study focused on adults who were already taking stable lipid-lowering therapies but still had elevated LDL-C levels.
Study Demographics:
- Participants: 2,912 adults across 14 countries.
- Average Age: 63 years.
- Gender: 39% women.
- Current Meds: Nearly all participants were on statins, and one-quarter were also taking ezetimibe.
The results, presented at #AHA25, were significant. According to Ann Marie Navar, M.D., Ph.D., an Associate Professor of Internal Medicine, “Enlicitide, an oral PCSK9 inhibitor, led to reductions in LDL and other cholesterol measures similar to injectable PCSK9 inhibitors.”
Why an Oral Alternative Matters
While injectable PCSK9 inhibitors are highly effective, they come with hurdles. Some patients have a phobia of needles, others struggle with the logistics of cold-storage for medications, and some simply find the injection process inconvenient. By offering a once-daily pill, enlicitide removes these barriers to adherence.
For patients with atherosclerotic cardiovascular disease (ASCVD) or those at high risk, the ability to consistently hit LDL targets is not just about numbers—it’s about preventing the next major cardiac event.
- Mechanism: Blocks PCSK9 to increase LDL receptor availability (same as injectables).
- Administration: Once-daily oral tablet vs. Subcutaneous injection.
- Target Audience: Adults with or at risk for ASCVD who don’t reach LDL targets on statins.
- Evidence: Phase 3 CORALreef Lipids Trial showed LDL reductions similar to injectable alternatives.
Frequently Asked Questions
Will this replace statins?
No. In the CORALreef Lipids Trial, nearly all participants were already taking statins. Enlicitide is designed as an add-on therapy for those who cannot reach their target LDL levels with statins and ezetimibe alone.
Who is the ideal candidate for enlicitide?
The primary candidates are adults with prior cardiovascular disease or those at high risk for ASCVD who have elevated LDL-C despite stable lipid-lowering therapy.
When will this be available?
The results from the phase 3 CORALreef Lipids Trial provide the critical efficacy and safety data required for regulatory review. Patients should consult their cardiologist or primary care physician to discuss the timeline for availability and whether this therapy is right for their specific health profile.
Looking Ahead
The transition from injectable to oral PCSK9 inhibitors represents a major leap in cardiovascular medicine. By combining the potency of monoclonal antibody-like mechanisms with the convenience of a pill, we are likely to see higher adherence rates and, a reduction in the global burden of heart attacks and strokes.